Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Credit Suisse 31st Annual Healthcare Conference
A virtual presentation will be made live starting on Tuesday, November 8, 2022
Stifel 2022 Healthcare Conference
Fireside chat: Wednesday, November 16, 2022 at 10:20 am EST
Location: Lotte New York Palace Hotel, New York, NY
Jefferies London Healthcare Conference
Fireside chat: Thursday, November 17, 2022 at 3:15 pm GMT (10:15 am EST)
Location: The Waldorf Hilton, London, UK
A live webcast and archived replay of the fireside chats along with a replay of the pre-recorded presentation will be available on the investors section of www.vorbio.com.
About Vor Bio
Vor Bio is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contact:
Media & Investors
Sarah Spencer
+1 857-242-6076
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.21 |
| Daily Change: | -0.14 -5.96 |
| Daily Volume: | 3,654,074 |
| Market Cap: | US$276.160M |
July 21, 2025 June 25, 2025 June 25, 2025 March 20, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
